Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1961 1
1968 4
1969 2
1970 1
1987 1
1988 1
2007 4
2008 3
2009 1
2010 2
2011 2
2012 3
2013 2
2014 3
2015 2
2016 1
2017 3
2018 2
2019 4
2020 7
2021 10
2022 6
2023 9
2024 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Results by year

Filters applied: . Clear all
Page 1
Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19.
Krämer B, Knoll R, Bonaguro L, ToVinh M, Raabe J, Astaburuaga-García R, Schulte-Schrepping J, Kaiser KM, Rieke GJ, Bischoff J, Monin MB, Hoffmeister C, Schlabe S, De Domenico E, Reusch N, Händler K, Reynolds G, Blüthgen N, Hack G, Finnemann C, Nischalke HD, Strassburg CP, Stephenson E, Su Y, Gardner L, Yuan D, Chen D, Goldman J, Rosenstiel P, Schmidt SV, Latz E, Hrusovsky K, Ball AJ, Johnson JM, Koenig PA, Schmidt FI, Haniffa M, Heath JR, Kümmerer BM, Keitel V, Jensen B, Stubbemann P, Kurth F, Sander LE, Sawitzki B; Deutsche COVID-19 OMICS Initiative (DeCOI); Aschenbrenner AC, Schultze JL, Nattermann J. Krämer B, et al. Immunity. 2021 Nov 9;54(11):2650-2669.e14. doi: 10.1016/j.immuni.2021.09.002. Epub 2021 Sep 4. Immunity. 2021. PMID: 34592166 Free PMC article.
Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma.
Rade M, Grieb N, Weiss R, Sia J, Fischer L, Born P, Boldt A, Fricke S, Franz P, Scolnick J, Venkatraman L, Xu S, Kloetzer C, Heyn S, Kubasch AS, Baber R, Wang SY, Bach E, Hoffmann S, Ussmann J, Schetschorke B, Hell S, Schwind S, Metzeler KH, Herling M, Jentzsch M, Franke GN, Sack U, Köhl U, Platzbecker U, Reiche K, Vucinic V, Merz M. Rade M, et al. Among authors: reiche k. Nat Cancer. 2024 Sep;5(9):1318-1333. doi: 10.1038/s43018-024-00763-8. Epub 2024 Apr 19. Nat Cancer. 2024. PMID: 38641734
Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma.
Fischer L, Grieb N, Born P, Weiss R, Seiffert S, Boldt A, Fricke S, Franz P, Heyn S, Kubasch AS, Baber R, Weidner H, Wang SY, Bach E, Hoffmann S, Ussmann J, Kirchberg J, Hell S, Schwind S, Metzeler KH, Herling M, Jentzsch M, Franke GN, Sack U, Reiche K, Köhl U, Platzbecker U, Vucinic V, Merz M. Fischer L, et al. Among authors: reiche k. Leukemia. 2024 Feb;38(2):372-382. doi: 10.1038/s41375-023-02129-y. Epub 2024 Jan 6. Leukemia. 2024. PMID: 38184754 Free PMC article.
Teclistamab impairs detection of BCMA CAR-T cells.
Glatte B, Wenk K, Grahnert A, Friedrich M, Merz M, Vucinic V, Fischer L, Reiche K, Alb M, Hudecek M, Franz P, Fricke S, Platzbecker U, Koehl U, Sack U, Boldt A, Hauschildt S, Weiss R. Glatte B, et al. Among authors: reiche k. Blood Adv. 2023 Aug 8;7(15):3842-3845. doi: 10.1182/bloodadvances.2023009714. Blood Adv. 2023. PMID: 37026812 Free PMC article. No abstract available.
Bioinformatics for RNomics.
Reiche K, Schutt K, Boll K, Horn F, Hackermüller J. Reiche K, et al. Methods Mol Biol. 2011;719:299-330. doi: 10.1007/978-1-61779-027-0_14. Methods Mol Biol. 2011. PMID: 21370090
Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed/refractory multiple myeloma.
Fandrei D, Seiffert S, Rade M, Rieprecht S, Gagelmann N, Born P, Wiemers T, Weidner H, Kreuz M, Schassberger T, Kossmann J, Mangold M, Furst D, Fischer L, Baber R, Heyn S, Wang SY, Bach E, Hoffmann S, Metzeler KH, Herlling M, Jentzsch M, Franke GN, Kohl U, Friedrich M, Boldt A, Reiche K, Platzbecker U, Vucinic V, Merz M. Fandrei D, et al. Among authors: reiche k. Blood Cancer Discov. 2024 Oct 23. doi: 10.1158/2643-3230.BCD-24-0118. Online ahead of print. Blood Cancer Discov. 2024. PMID: 39441177
Alzheimer-related genes show accelerated evolution.
Nitsche A, Arnold C, Ueberham U, Reiche K, Fallmann J, Hackermüller J, Horn F, Stadler PF, Arendt T. Nitsche A, et al. Among authors: reiche k. Mol Psychiatry. 2021 Oct;26(10):5790-5796. doi: 10.1038/s41380-020-0680-1. Epub 2020 Mar 13. Mol Psychiatry. 2021. PMID: 32203153 Free PMC article.
Time to evolve: predicting engineered T cell-associated toxicity with next-generation models.
Donnadieu E, Luu M, Alb M, Anliker B, Arcangeli S, Bonini C, De Angelis B, Choudhary R, Espie D, Galy A, Holland C, Ivics Z, Kantari-Mimoun C, Kersten MJ, Köhl U, Kuhn C, Laugel B, Locatelli F, Marchiq I, Markman J, Moresco MA, Morris E, Negre H, Quintarelli C, Rade M, Reiche K, Renner M, Ruggiero E, Sanges C, Stauss H, Themeli M, Van den Brulle J, Hudecek M, Casucci M. Donnadieu E, et al. Among authors: reiche k. J Immunother Cancer. 2022 May;10(5):e003486. doi: 10.1136/jitc-2021-003486. J Immunother Cancer. 2022. PMID: 35577500 Free PMC article. Review.
Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?
Guedan S, Luu M, Ammar D, Barbao P, Bonini C, Bousso P, Buchholz CJ, Casucci M, De Angelis B, Donnadieu E, Espie D, Greco B, Groen R, Huppa JB, Kantari-Mimoun C, Laugel B, Mantock M, Markman JL, Morris E, Quintarelli C, Rade M, Reiche K, Rodriguez-Garcia A, Rodriguez-Madoz JR, Ruggiero E, Themeli M, Hudecek M, Marchiq I. Guedan S, et al. Among authors: reiche k. J Immunother Cancer. 2022 May;10(5):e003487. doi: 10.1136/jitc-2021-003487. J Immunother Cancer. 2022. PMID: 35577501 Free PMC article. Review.
76 results